These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9641502)

  • 1. A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids.
    Olin R; Klein R; Berg PA
    Clin Rheumatol; 1998; 17(2):89-94. PubMed ID: 9641502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders.
    Klein R; Berg PA
    Eur J Med Res; 1995 Oct; 1(1):21-6. PubMed ID: 9392689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia-myalgia syndrome.
    Klein R; Berg PA
    Clin Investig; 1994 Jul; 72(7):541-9. PubMed ID: 7981584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Incidence and clinical relevance of antibodies to phospholipids, serotonin and ganglioside in patients with sudden deafness and progressive inner ear hearing loss].
    Heller U; Becker EW; Zenner HP; Berg PA
    HNO; 1998 Jun; 46(6):583-6. PubMed ID: 9677490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome.
    Klein R; Bänsch M; Berg PA
    Psychoneuroendocrinology; 1992 Nov; 17(6):593-8. PubMed ID: 1287679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial.
    Akhondzadeh S; Mohajari H; Reza Mohammadi M; Amini H
    BMC Psychiatry; 2003 Jun; 3():7. PubMed ID: 12816549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome.
    Werle E; Fischer HP; Müller A; Fiehn W; Eich W
    J Rheumatol; 2001 Mar; 28(3):595-600. PubMed ID: 11296965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
    Abi-Saab W; Seibyl JP; D'Souza DC; Karper LP; Gueorgueva R; Abi-Dargham A; Wong ML; Rajhans S; Erdos JP; Heninger GR; Charney DS; Krystal JH
    Psychopharmacology (Berl); 2002 Jun; 162(1):55-62. PubMed ID: 12107618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group.
    Johnson BA; Jasinski DR; Galloway GP; Kranzler H; Weinreib R; Anton RF; Mason BJ; Bohn MJ; Pettinati HM; Rawson R; Clyde C
    Psychopharmacology (Berl); 1996 Nov; 128(2):206-15. PubMed ID: 8956382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin.
    Bersani G; Pozzi F; Marini S; Grispini A; Pasini A; Ciani N
    Acta Psychiatr Scand; 1991 Apr; 83(4):244-8. PubMed ID: 1903019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ritanserin improves sleep quality in narcolepsy.
    Mayer G
    Pharmacopsychiatry; 2003 Jul; 36(4):150-5. PubMed ID: 12905101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group.
    Wiesbeck GA; Weijers HG; Chick J; Naranjo CA; Boening J
    Alcohol Clin Exp Res; 1999 Feb; 23(2):230-5. PubMed ID: 10069551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
    Bersani G; Grispini A; Marini S; Pasini A; Valducci M; Ciani N
    Clin Neuropharmacol; 1990 Dec; 13(6):500-6. PubMed ID: 2125857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers.
    Viola AU; Brandenberger G; Toussaint M; Bouhours P; Paul Macher J; Luthringer R
    Clin Neurophysiol; 2002 Mar; 113(3):429-34. PubMed ID: 11897543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers.
    van Laar M; Volkerts E; Verbaten M
    Psychopharmacology (Berl); 2001 Mar; 154(2):189-97. PubMed ID: 11314681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam.
    Ceulemans DL; Hoppenbrouwers ML; Gelders YG; Reyntjens AJ
    Pharmacopsychiatry; 1985 Sep; 18(5):303-5. PubMed ID: 3931107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibromyalgia treatment with intravenous tropisetron administration.
    Stratz T; Färber L; Varga B; Baumgartner C; Haus U; Müller W
    Drugs Exp Clin Res; 2001; 27(3):113-8. PubMed ID: 11447769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam.
    Bressa GM; Marini S; Gregori S
    Int J Clin Pharmacol Res; 1987; 7(2):111-9. PubMed ID: 3108171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease.
    Henderson J; Yiannikas C; Graham JS
    Clin Exp Neurol; 1992; 29():277-82. PubMed ID: 1343870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.